bluebird bio (NASDAQ:BLUE) Given “Sector Perform” Rating at Royal Bank of Canada

bluebird bio (NASDAQ:BLUE)‘s stock had its “sector perform” rating reissued by equities research analysts at Royal Bank of Canada in a report released on Friday,Benzinga reports. They currently have a $4.00 target price on the biotechnology company’s stock.

BLUE has been the topic of several other reports. Barclays cut their price target on shares of bluebird bio from $4.00 to $2.00 and set an “overweight” rating on the stock in a research report on Friday. Robert W. Baird cut their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. StockNews.com began coverage on shares of bluebird bio in a report on Sunday, November 10th. They set a “sell” rating on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. cut bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $3.03.

bluebird bio Trading Down 11.4 %

Shares of bluebird bio stock traded down $0.04 during trading hours on Friday, hitting $0.32. The company’s stock had a trading volume of 6,895,475 shares, compared to its average volume of 7,427,930. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. The business has a fifty day moving average of $0.49 and a 200 day moving average of $0.79. The company has a market capitalization of $62.26 million, a PE ratio of -0.14 and a beta of 0.76. bluebird bio has a 1-year low of $0.32 and a 1-year high of $5.53.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. The business had revenue of $18.57 million for the quarter. As a group, equities analysts forecast that bluebird bio will post -1.41 EPS for the current year.

Institutional Investors Weigh In On bluebird bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allegheny Financial Group LTD purchased a new stake in shares of bluebird bio in the 2nd quarter valued at about $25,000. Verition Fund Management LLC purchased a new position in bluebird bio in the 3rd quarter worth approximately $42,000. Bayesian Capital Management LP bought a new position in bluebird bio during the 1st quarter valued at $52,000. SG Americas Securities LLC raised its position in shares of bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 74,185 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 29,113 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.